These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 23882028)
1. Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics. Tzouros M; Golling S; Avila D; Lamerz J; Berrera M; Ebeling M; Langen H; Augustin A Mol Cell Proteomics; 2013 Nov; 12(11):3339-49. PubMed ID: 23882028 [TBL] [Abstract][Full Text] [Related]
2. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012 [TBL] [Abstract][Full Text] [Related]
3. Deep Phosphotyrosine Proteomics by Optimization of Phosphotyrosine Enrichment and MS/MS Parameters. Abe Y; Nagano M; Tada A; Adachi J; Tomonaga T J Proteome Res; 2017 Feb; 16(2):1077-1086. PubMed ID: 28152594 [TBL] [Abstract][Full Text] [Related]
4. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. Zhang G; Fang B; Liu RZ; Lin H; Kinose F; Bai Y; Oguz U; Remily-Wood ER; Li J; Altiok S; Eschrich S; Koomen J; Haura EB J Proteome Res; 2011 Jan; 10(1):305-19. PubMed ID: 21080693 [TBL] [Abstract][Full Text] [Related]
5. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. DeFazio-Eli L; Strommen K; Dao-Pick T; Parry G; Goodman L; Winslow J Breast Cancer Res; 2011 Apr; 13(2):R44. PubMed ID: 21496232 [TBL] [Abstract][Full Text] [Related]
6. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047 [TBL] [Abstract][Full Text] [Related]
7. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Huang H; Haar Petersen M; Ibañez-Vea M; Lassen PS; Larsen MR; Palmisano G Mol Cell Proteomics; 2016 Oct; 15(10):3282-3296. PubMed ID: 27281782 [TBL] [Abstract][Full Text] [Related]
12. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028 [TBL] [Abstract][Full Text] [Related]
13. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604 [TBL] [Abstract][Full Text] [Related]
14. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502 [TBL] [Abstract][Full Text] [Related]
15. FAIMS and Phosphoproteomics of Fibroblast Growth Factor Signaling: Enhanced Identification of Multiply Phosphorylated Peptides. Zhao H; Cunningham DL; Creese AJ; Heath JK; Cooper HJ J Proteome Res; 2015 Dec; 14(12):5077-87. PubMed ID: 26503514 [TBL] [Abstract][Full Text] [Related]
16. Deep Coverage of Global Protein Expression and Phosphorylation in Breast Tumor Cell Lines Using TMT 10-plex Isobaric Labeling. Huang FK; Zhang G; Lawlor K; Nazarian A; Philip J; Tempst P; Dephoure N; Neubert TA J Proteome Res; 2017 Mar; 16(3):1121-1132. PubMed ID: 28102081 [TBL] [Abstract][Full Text] [Related]
17. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Zhang Y; Wolf-Yadlin A; Ross PL; Pappin DJ; Rush J; Lauffenburger DA; White FM Mol Cell Proteomics; 2005 Sep; 4(9):1240-50. PubMed ID: 15951569 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. Stebbing J; Zhang H; Xu Y; Grothey A; Ajuh P; Angelopoulos N; Giamas G Mol Cell Proteomics; 2015 Sep; 14(9):2479-92. PubMed ID: 26089344 [TBL] [Abstract][Full Text] [Related]
19. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. Xie H; Lin L; Tong L; Jiang Y; Zheng M; Chen Z; Jiang X; Zhang X; Ren X; Qu W; Yang Y; Wan H; Chen Y; Zuo J; Jiang H; Geng M; Ding J PLoS One; 2011; 6(7):e21487. PubMed ID: 21789172 [TBL] [Abstract][Full Text] [Related]
20. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Imami K; Sugiyama N; Imamura H; Wakabayashi M; Tomita M; Taniguchi M; Ueno T; Toi M; Ishihama Y Mol Cell Proteomics; 2012 Dec; 11(12):1741-57. PubMed ID: 22964224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]